RBMS1 Deficiency Improves Heart Failure 01/05/26

Welcome to Cardiology Today – Recorded January 05, 2026. This episode summarizes 5 key cardiology studies on topics like left ventricular diastolic dysfunction and transcatheter aortic valve replacement. Key takeaway: RBMS1 Deficiency Improves Heart Failure. Article Links: Article 1: Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score. (European heart journal) Article 2: Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure. (European heart journal) Article 3: Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study. (International journal of cardiology) Article 4: Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up. (International journal of cardiology) Article 5: Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function. (Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography) Full episode page: https://podcast.explainheart.com/podcast/rbms1-deficiency-improves-heart-failure-01-05-26/ Featured Articles Article 1: Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40678978 Summary: Researchers identified a cohort of 337 patients with non-dilated left ventricular cardiomyopathy, or NDLVC, without prior major arrhythmic events. The study developed a novel prediction score for the occurrence of the first major arrhythmic event in this patient population. Diagnostic workup including cardiac magnetic resonance, endomyocardial biopsy, and genetic testing contributed to the elements comprising this score. This prediction score facilitates improved risk stratification for serious arrhythmias in non-dilated left ventricular cardiomyopathy. Article 2: Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40471706 Summary: This study found that a deficiency of RNA-binding motif single-stranded interacting protein 1, or RBMS1, significantly improved both myocardial fibrosis and heart failure. Researchers observed that RBMS1 levels were elevated in the hearts of heart failure patients and animal models. The deficiency of RBMS1 regulated alternative splicing, which subsequently reduced cardiac fibrosis. These findings demonstrate RBMS1 as a novel therapeutic target for heart failure and myocardial fibrosis. Article 3: Coronary access after TAVR with the 4th and 5th -generation self-expanding Evolut valves: The EPROMPT-CA study. Journal: International journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41485619 Summary: This prospective study assessed coronary access immediately following transcatheter aortic valve replacement, or TAVR, using fourth and fifth-generation self-expanding Evolut F. X. and F. X. Plus valves. Researchers identified specific computed tomography predictors for selective coronary access in patients who underwent transfemoral TAVR. The study established the anatomical determinants that impact the feasibility of subsequent coronary interventions. These findings offer practical guidance for optimizing post-TAVR coronary access strategies in patients implanted with these latest Evolut valve platforms. Article 4: Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up. Journal: International journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41485617 Summary: This retrospective cohort study compared 454 patients with primary pulmonary hypertension receiving sotatercept to 963386 primary pulmonary hypertension patients who did not receive the treatment. Researchers utilized data from a global federated health research network to analyze real-world long-term outcomes. The study established a comprehensive comparison of patient trajectories between the sotatercept-treated and untreated cohorts over an extended follow-up period. These findings offer critical data on the sustained real-world impact of sotatercept in pulmonary hypertension beyond short-term trial observations. Article 5: Impact of Left Ventricular Diastolic Function on Right Ventricular Size and Function. Journal: Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41485609 Summary: This study investigated the impact of various degrees of left ventricular diastolic dysfunction, or D. D., on right ventricular size and function. Researchers performed 3-dimensional imaging of the right ventricle in a broad sample of 370 patients undergoing echocardiography. The study established a direct relationship between lesser degrees of left ventricular ...